Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. has announced encouraging results from their PARADIGM Phase 2b study, showing that their drug PrimeC significantly slows disease progression and improves survival rates in ALS patients. The study revealed a 36% improvement in disease progression and a 43% better survival rate for patients treated with PrimeC compared to those receiving a placebo. These results are paving the way for a Phase 3 clinical study in the U.S. and Europe, highlighting PrimeC’s potential as a game-changing ALS treatment.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
